EcoDrugPlus

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSPLAG00000016187
Gene Symbol: PIK3R3
3 Cross references
147 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSPLAG00000011941
Gene Symbol: PIK3R3
3 Cross references
206 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSPLAG00000003862
Gene Symbol: PIK3R5
3 Cross references
200 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSPLAG00000020478
Gene Symbol: PLA2G7
3 Cross references
203 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSPLAG00000020492
Gene Symbol: PLA2G10
1 Cross references
231 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSPLAG00000020501
Gene Symbol: PLA2G10
1 Cross references
231 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSPLAG00000002833
Gene Symbol: GART
3 Cross references
246 Possible Orthologues:

Plasma Kallikrein-Like

Ensembl ID : ENSPLAG00000001897
Gene Symbol: LOC106958351
2 Cross references
183 Possible Orthologues:

Plasma Kallikrein-Like

Ensembl ID : ENSPLAG00000001937
Gene Symbol: LOC106958355
2 Cross references
185 Possible Orthologues:

Plasminogen

Ensembl ID : ENSPLAG00000008107
Gene Symbol: PLG
1 Cross references
248 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSPLAG00000015756
Gene Symbol: PLAT
3 Cross references
205 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSPLAG00000015665
Gene Symbol: PTAFR
1 Cross references
224 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).